Navigation Links
Valeant Pharmaceuticals Increases Proposed Price for Acquisition of ISTA Pharmaceuticals Inc. to $7.50 Per Share in Cash
Date:1/17/2012

is not acting to enter into our premium transaction while it is available, rather than chase a theoretical other offer that may not materialize. 

If ISTA is interested in pursuing our proposal in order to benefit its shareholders, we are prepared to move very quickly, and believe that with your cooperation we could complete our diligence review within one week of receipt of the materials.  When we announced our proposal to acquire ISTA, we were very clear that our offer would only remain open until January 31, and we have continued to be clear on that point.  We believe that this timeframe was when made, and remains today, adequate time to perform due diligence and enter into an agreement if ISTA is willing to engage itself and commit the necessary resources.  We already have devoted substantial time and resources to evaluating an acquisition of ISTA, and we still intend to move on to other opportunities if we do not have a clear path to a transaction by January 31, 2012.

ISTA's Board must be aware of the risks associated with failing to pursue our proposal.  We believe that ISTA's recent stock price rise is attributable to our offer and the possibility of a sale of ISTA, and not to the fundamentals of ISTA's business or projections of future performance.  Our increased proposed price of $7.50 pre-diligence and potential for $8.50 after diligence represent a 94% and 120% premium, respectively, to ISTA's 60-day volume weighted average price of $3.87 on December 15, 2011, the last trading day before public announcement of our offer.  Our offer continues to represent a compelling opportunity for ISTA's shareholders in light of the continuing challenges facing ISTA.

We intend to make our improved proposal public tomorrow, because we believe ISTA's stockholders have a right to consider this improved offer, learn about the lack of progress we have made together to date and understand that the Board is placing our o
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Fleming Pharmaceuticals Sells Ocean, Nephrocaps, Other Branded Products to Valeant
2. Valeant Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference
3. Valeant Pharmaceuticals Completes Acquisition of iNova
4. Valeant Pharmaceuticals to Hold Conference Call to Announce 2012 Financial Guidance
5. Valeant Pharmaceuticals Completes Acquisition of Dermik
6. Valeant Announces Successful Results From Phase III Onychomycosis Trials
7. Valeant Announces the Completion of the Privatization of Afexa Life Sciences Inc.
8. Valeant Pharmaceuticals Receives Approval From FTC in Connection With Acquisition of Ortho Dermatologics and Dermik
9. Valeant Pharmaceuticals to Syndicate Incremental Term Loans
10. Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer
11. Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... FRANCISCO, Calif. , Aug. 28, 2015  CytomX ... the treatment of cancer, today announced the filing of ... Securities and Exchange Commission (SEC) relating to a proposed ... of shares to be offered and the price range ... intends to list its common stock under the symbol ...
(Date:8/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/jq34zf/investigation ) ... on China,s Tobramycin Market, 2010-2019" report to their ... eye drop and ointment are the most common prescription ... caused by eye infection. Currently, dozens of enterprises in ... tobramycin, among which the Top 5 are s.a. Alcon- ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Developed by Pharmacia ... prostaglandin receptor agonist which effectively reduces intraocular pressure. ... FDA, latanoprost (under the trade name of Xalatan) ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Tobramycin Market, 2015-2019 2China Latanoprost Market Investigation Report 2015-2019 2
... 5, 2011 eCareSoft announced today the completion of ... their network of six hospitals with eCareSoft,s inpatient complete ... will incorporate eCareSoft,s proprietary fast-track implementation program enabling their ... order to qualify for 2011-2012 stimulus funds. ...
... EXTON, Pa., April 4, 2011 Morphotek®, Inc., ... it has acquired certain assets relating to a ... for an undisclosed upfront payment and future development ... of Prussia, PA, developed the tumor-targeting peptide (TTP) ...
Cached Medicine Technology:Central Texas Hospital Selects eCareSoft EHR Technology 2Morphotek®, Inc. Announces Acquisition of Tumor Targeting Assets From Transmolecular, Inc. 2Morphotek®, Inc. Announces Acquisition of Tumor Targeting Assets From Transmolecular, Inc. 3
(Date:8/31/2015)... IL (PRWEB) , ... August 31, 2015 , ... In ... studies, Etymotic Research, maker of the BEAN™ personal sound amplifier, is offering caregivers “7 ... sound amplifiers as a way of coping with a variety of home healthcare challenges, ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... association for physicians and allied health professionals dedicated to using lifestyle as ... today the establishment of the Lifestyle Medicine Lifetime Achievement and Trailblazer Awards, ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... nonprofit authority on the use of health IT to create efficiencies in healthcare ... WEDI-Con 2015 . Taking place at the Hyatt Regency Reston in Reston, ...
(Date:8/31/2015)... YORK & ATLANTA (PRWEB) , ... ... ... a technology and information security executive networking and relationship-marketing firm, announced today ... the Year Awards in the Northeast U.S. Region. Executives include top-ranking decision ...
(Date:8/31/2015)... ... August 31, 2015 , ... Now through October 31st, ... will be featured on a digital screen projected above New York’s Times Square, ... and promote earlier awareness of the symptoms of ovarian cancer, and earlier conversations ...
Breaking Medicine News(10 mins):Health News:Etymotic Offers Caregivers “7 Reasons to Care about Hearing Health” 2Health News:Etymotic Offers Caregivers “7 Reasons to Care about Hearing Health” 3Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 2Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 3Health News:WEDI Announces Program for Annual Fall Conference: WEDI-Con 2015 2Health News:WEDI Announces Program for Annual Fall Conference: WEDI-Con 2015 3Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 2Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 3Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 4Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 2Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 3
... , THURSDAY, Feb. 24 (HealthDay News) -- ... risk of cancer due to high radiation doses, and ... radiation exposure, a new study suggests. The researchers ... dialysis also have other health conditions that require them ...
... Association for Gerontology in Higher Education (AGHE) the ... will hold its 37th Annual Meeting and Educational ... Hilton Cincinnati Netherland Plaza in Cincinnati, OH. ... This conference provides a forum for professionals in the ...
... SEATTLE Full-term pregnancy has long been associated with a ... that the more times a woman gives birth, the higher ... particularly aggressive subtype of the disease. Conversely, women who never ... breast cancer, which has a poorer prognosis than other types ...
... donor-liver distribution network developed by University of Pittsburgh researchers ... receiving the transplants they need. The team reports ... donor livers currently are doled out to 11 national ... demographics, an arrangement that prevents many livers from getting ...
... and many of the factors reported by those who say they ... survey of its kind, published in the launch issue of the ... likely to challenge the perception that these patients can no longer ... suicide, say the authors. The research team quizzed 168 members ...
... -- Gender does not appear to have any impact on ... research indicates. The study authors observed that female heart ... in fact, more likely to subsequently die than male patients. ... a function of gender, but rather of the fact that ...
Cached Medicine News:Health News:Many Dialysis Patients at Risk for High Radiation Exposure 2Health News:As America's senior population grows, meeting to outline effective education about aging 2Health News:Multiple childbirth linked to increased risk of rare, aggressive 'triple-negative' breast cancer 2Health News:Multiple childbirth linked to increased risk of rare, aggressive 'triple-negative' breast cancer 3Health News:Redesign of US donor-liver network could boost transplants by several hundred per year 2Health News:Redesign of US donor-liver network could boost transplants by several hundred per year 3Health News:Most 'locked-in syndrome' patients say they are happy 2Health News:Severe Heart Attack No More Deadly to Women Than Men 2
Bipolar forceps...
... Nucleic Acid Hybridization Assay with ... for the Qualitative Detection of ... and 68 and Analysis of ... in Cervical Specimens: HPV Types ...
... radiation protection-0.62mm (+/- .05)Pb lead glass equivelant ... their level of protection, they are incredibly ... on your bridge while hugging your face ... corrective lenses, you can order Leaded Eyeglasses ...
... in the world, there is a now a ... VVC in female patients. CanDia5® is a simple-to-use, ... Candida antigens almost instantaneously (within 5 minutes) with ... is no similar POC product for VVC diagnosis ...
Medicine Products: